Assurance de qualité pour le cancer rectal – phase 2 ...

156 PROCARE – phase 2 KCE reports 81Proportion of stage II-III patients treated with neoadjuvant5-FU based chemoradiation, that received a continuousinfusion of 5-FUProportion of stage II-III patients treated with a longcourse of preoperative pelvic RT or chemoradiation, thatcompleted this neoadjuvant treatment within the plannedtimingProportion of stage II-III patients treated with a longcourse of preoperative pelvic RT or chemoradiation, thatwas operated 6 to 8 weeks after completion of the(chemo)radiationRate of acute grade 4 radio(chemo)therapy-relatedcomplicationsBavaria Burgundy North NL SW SPAIN UK DK NNo Not used No No No No No NoNo No No Yes No No No NoNo Yes No * Yes Yes No No YesNo No No No No No No NoPatients treated with local excision or TEMS by stage/level No Yes Yes Yes Yes Yes Yes YesProportion of R0 resections per stage/level No Yes Yes Yes Yes No Yes YesProportion of APR and Hartmann’s procedures perNo Yes Yes Yes Yes Yes Yes Yesstage/levelProportion of patients undergoing sphincter-sparingNo Yes No Yes Yes Yes No Nosurgery with/without temporary stoma at primarysurgery, still having their stoma 1y after surgeryRate of patients with major leakage of the anastomosis No No limited Yes Yes Yes Yesafter SSOInpatient or 30-day mortality No Yes Yes Yes Yes Yes Yes YesRate of intra-operative tumour soiling No Yes No * No No ? Yes YesProportion of stage II-III patients that received adjuvant No Yes Yes Yes Yes Yes No Not usedchemotherapyProportion of stage II-III patients that received adjuvantradiotherapy or chemoradiotherapy if no neoadjuvantNo Yes Yes Yes Yes Yes No Yes (forRT)therapyProportion of stage II-III patients that started adjuvantchemotherapy within 1 month after surgical resectionNo Yes No Yes No Yes No Not used